Daiichi Sankyo Press Release

12/14/2017 - 02:57 Winners of 10th Manpei Suzuki International Prize for Diabetes Research and 11th Manpei Suzuki Prize for Diabetes Care and Education Announced
12/12/2017 - 20:49 Once-Daily, Oral LIXIANA (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study
12/12/2017 - 18:06 Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
12/07/2017 - 18:35 Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer at San Antonio Breast Cancer Symposium
12/06/2017 - 21:54 Daiichi Sankyos Subsidiary Daiichi Sankyo Espha to Launch New Generic Drugs
11/30/2017 - 20:39 Daiichi Sankyo and Translational Sciences Conclude Agreement, after Successful Phase 1a Trial, as Part of Daiichi Sankyo Portfolio Prioritization
11/29/2017 - 23:33 Daiichi Sankyo to Absorb Japan Research Subsidiary, Asubio Pharma Co., Ltd.
11/29/2017 - 21:07 Daiichi Sankyo to Convert Kitasato Daiichi Sankyo Vaccine into Wholly Owned Subsidiary
11/28/2017 - 22:11 Daiichi Sankyo Launches Anticoagulant Lixiana OD Tablets (orally disintegrating tablets) in Japan
11/20/2017 - 22:44 Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Advanced Gastric Cancer
11/14/2017 - 19:46 New LIXIANA sub-analysis from the ENGAGE AF-TIMI 48 trial presented at the American Heart Association Annual Scientific Sessions 2017
10/29/2017 - 23:18 Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing
10/15/2017 - 22:34 Commencement of Collaborative Research on Measurement of Exosomes in Blood from Cancer Patients
10/10/2017 - 18:18 Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct JOINUS, a New Drug Discovery Program Using Drug-Repositioning Compound Library
09/29/2017 - 03:17 Daiichi Sankyo Underwrites All Shares Issued by Kitasato Daiichi Sankyo Vaccine
09/25/2017 - 17:21 Daiichi Sankyo Announces TaNeDS Global 2018 Collaborative Drug Discovery Program
09/24/2017 - 19:15 Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Study in Japan of Esaxerenone for Treatment of Essential Hypertension
09/14/2017 - 18:37 Daiichi Sankyo Listed on the Dow Jones Sustainability Indices World Index
09/14/2017 - 17:14 MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myeloid Leukemia Therapies
09/11/2017 - 17:51 Daiichi Sankyo Presents New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors at European Society for Medical Oncology (ESMO) 2017 Congress
09/06/2017 - 20:06 Sanford Burnham Prebys and Daiichi Sankyo Announce Enrollment of First Subject in a Phase 1 Clinical Trial of DS-1211 in Healthy Volunteers
09/06/2017 - 19:40 Japans First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug Launch of CANALIA Combination Tablets, a type 2 diabetes mellitus treatment agent
08/31/2017 - 21:44 Restriction on prescription period lifted for antiepileptic VIMPAT Tablets 50 mg and 100 mg
08/31/2017 - 01:27 Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108
08/31/2017 - 00:22 Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabalin in Diabetic Peripheral Neuropathic Pain
08/29/2017 - 20:56 Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Metastatic Breast Cancer
08/29/2017 - 19:01 FDA Grants Breakthrough Therapy Designation to Daiichi Sankyos DS-8201 for HER2-Positive Metastatic Breast Cancer
08/28/2017 - 17:40 Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitorfor Solid Tumors
08/28/2017 - 02:51 Daiichi Sankyo Announces New Oxycodone Tablets "Daiichi Sankyo" for Cancer Pain Treatment in Japan
08/25/2017 - 02:30 Antiepileptic VIMPAT Tablets 50 mg and 100 mg approved for monotherapy for Partial-onset Seizures in Epilepsy Patients
08/25/2017 - 00:38 Daiichi Sankyo Obtains Approval in Japan for Additional Indication and Dosage for Ovisot for Injection in Diagnosis of Vasospastic Angina
08/06/2017 - 20:06 Daiichi Sankyo to Collaborate on Commercialization of Generic Transdermal Fentanyl Citrate Patches for Long-Acting Cancer Pain Relief
08/06/2017 - 18:39 Daiichi Sankyo Invests in Osaka University Spin-Off Venture with the Aim of Commercializing iPS-derived Cardiomyocyte Sheet
08/01/2017 - 15:40 Daiichi Sankyo Announces Settlement Agreement on U.S. Products Liability Litigation
07/19/2017 - 17:43 Daiichi Sankyo Opens Applications for Investigator-Initiated Studies Program
07/18/2017 - 18:11 Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody Collaboration
07/18/2017 - 01:38 Daiichi Sankyo Announces Completion of Payment Concerning Disposal of Treasury Shares as Restricted Share-Based Remuneration
07/11/2017 - 18:18 Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration
07/10/2017 - 20:07 Oncolytic Virus G47 (DS-1647) designated as Orphan Drug under Orphan Drug/Medical Device Designation System
07/10/2017 - 19:36 Daiichi Sankyo Selected for Ninth Consecutive Year as Constituent of FTSE4Good Global Index by FTSE Russell
07/02/2017 - 20:31 Daiichi Sankyo Obtains Approval for Additional Indication for PRALIA Subcutaneous Injection 60mg Syringe
07/02/2017 - 19:39 Japans First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug Application approved in Japan for CANALIA Combination Tablets, a type 2 diabetes mellitus treatment agent
06/29/2017 - 20:28 Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes
06/18/2017 - 19:41 Daiichi Sankyo Announces Disposal of Treasury Shares as Restricted Share-Based Remuneration
06/18/2017 - 18:22 Daiichi Sankyo Announces Launch of Narurapid Tablets and Narusus Tablets for Cancer Pain Treatment
06/05/2017 - 18:22 New Precision Medicine Data on DS-8201 in HER2-Expressing Breast Cancer Revealed at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
05/10/2017 - 22:44 Representative: Sunao Manabe, Representative Director, President and COO
05/10/2017 - 21:26 Differences Between Consolidated Results for Fiscal 2016 and Fiscal 2015
04/28/2017 - 03:39 Daiichi Sankyo Revises Fiscal 2016 Consolidated Forecasts and Announces Fiscal 2017 Consolidated Forecasts
04/28/2017 - 03:26 Daiichi Sankyo Announces the Introduction of a Restricted Share-Based Remuneration Plan
04/28/2017 - 00:57 Daiichi Sankyo Announces Impairment Loss Related to Kitasato Daiichi Sankyo Vaccine
04/26/2017 - 22:24 Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio
04/21/2017 - 18:16 Daiichi Sankyo Initiates Pivotal Phase 3 study in Japan of Esaxerenone in Patients with Diabetic Nephropathy
04/03/2017 - 21:38 Daiichi Sankyo, Inc. Announces Sale of Pharmaceutical Packaging Plant in Bethlehem, PA
03/30/2017 - 20:46 Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily Lixiana (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation
03/29/2017 - 23:52 Daiichi Sankyo Announces Manufacture and Sales Approval in Japan of Narurapid Tablets and Narusus Tablets for Cancer Pain Treatment
03/29/2017 - 23:35 Daiichi Sankyo Submits Application for Additional Indication and Dosage for Ovisot Intracoronary Injection 0.1g in Diagnosis of Vasospastic Angina
03/22/2017 - 22:28 Daiichi Sankyo to Facilitate New Drug Discovery in 2017 through Collaborative Research and Grants
03/15/2017 - 21:50 National Institutes of Biomedical Innovation, Health and Nutrition
03/13/2017 - 00:06 Daiichi Sankyo Announces Large-scale Registry of Venous Thromboembolism (VTE) in Cancer Patients
03/12/2017 - 23:40 Daiichi Sankyo Enters Agreement with Heptares Therapeutics to Discover and Develop Novel, Small-Molecules for the Treatment of Pain
03/08/2017 - 00:14 Daiichi Sankyo Announces New Oxycodone Extended Release Tablets "Daiichi Sankyo" for Sustained Cancer Pain Treatment
02/21/2017 - 22:04 Daiichi Sankyo Joins IkuBoss Alliance
02/14/2017 - 21:37 Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha
02/03/2017 - 19:18 Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Receive Complete Response Letter from FDA for New Drug Application for CL-108 (hydrocodone, acetaminophen, promethazine) Tablets for Oral Use
01/30/2017 - 22:35 Daiichi Sankyo Announces New Chairman and President
01/18/2017 - 18:27 Daiichi Sankyo Initiates Phase 1/2 Study of Novel Antibody Drug Conjugate U3-1402 in Patients with HER3-Positive Metastatic or Unresectable Breast Cancer
12/01/2016 - 20:10 U.S. FDA Grants Fast Track Designation for HER2-Targeting Antibody Drug Conjugate DS-8201 for HER2-Positive Metastatic Breast Cancer
11/30/2016 - 01:13 Daiichi Sankyo Announces Japanese Research Partners Selected for 2016 TaNeDS Collaborative Drug Discovery Project
10/25/2016 - 19:53 Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond Formulated with SentryBond Abuse-Deterrent Technology
10/20/2016 - 23:18 ENLIVEN Phase 3 Study of Pexidartinib in Tenosynovial Giant Cell Tumor (TGCT) Will Continue to Completion Following Enrollment Discontinuation
10/20/2016 - 22:04 Daiichi Sankyo Announces Phase 3 Clinical Trial (PRASTRO-I Study, PRASTRO-II Study) Results for Prasugrel Antiplatelet Agent for Patients with Ischemic Cerebrovascular Disease
10/12/2016 - 06:37 Daiichi Sankyo and Dana-Farber Cancer Institute Announce Lung Cancer Research Collaboration
10/11/2016 - 21:07 Daiichi Sankyo Announces First Patient Enrolled in Phase 3 QuANTUM-First Trial Investigating Quizartinib in Newly-Diagnosed FLT3-ITD+ Acute Myeloid Leukemia
10/11/2016 - 20:47 Daiichi Sankyo Announces TaNeDS Europe 2017 Collaborative Drug Discovery Programme
10/04/2016 - 01:15 Daiichi Sankyo Announces New Strategic Immuno-Oncology Research Collaboration with AgonOx
09/28/2016 - 07:25 Zymeworks and Daiichi Sankyo Announce Immuno-Oncology Cross-Licensing Agreement and Bi-Specific Antibody Collaboration
09/23/2016 - 02:41 Daiichi Sankyo Announces Application in Japan for Additional Indication for Anti-RANKL Antibody, Denosumab
09/14/2016 - 01:27 Daiichi Sankyo Selected for Dow Jones Sustainability Asia Pacific Indices for Seventh Consecutive Year
08/30/2016 - 00:30 ENSURE-AF Data Support the Efficacy and Safety Profile of Daiichi Sankyos Once-Daily LIXIANA in Patients with Atrial Fibrillation Undergoing Cardioversion
08/25/2016 - 23:22 Daiichi Sankyo Receives Additional Dosage Regimen Approval in Japan for Long-acting Neuraminidase Inhibitor Inavir Dry Powder Inhaler 20mg
08/23/2016 - 22:14 Daiichi Sankyo Initiates ELDERCARE-AF Study of Anticoagulant Edoxaban
07/15/2016 - 01:00 Daiichi Sankyo Issues Unsecured Straight Bonds
07/14/2016 - 02:06 Amgen and Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
07/04/2016 - 21:37 Antiepileptic Drug Vimpat Tablets 50 mg and 100 mg have been launched.
07/04/2016 - 01:46 UCB and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VIMPAT) as adjunctive therapy in the treatment of partial-onset seizures in adult patients with epilepsy
06/30/2016 - 00:55 FTSE Russell Corporation Selects Daiichi Sankyo for FTSE4Good Global Index
06/27/2016 - 02:17 Daiichi Sankyo Enters Into Agreement with Servier Canada For Factor Xa Inhibitor Edoxaban
06/14/2016 - 01:07 Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce FDA Acceptance of New Drug Application (NDA) for CL-108
05/31/2016 - 01:05 Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer (NSCLC)
05/25/2016 - 02:37 Daiichi Sankyo Launches Antiplatelet Agent Efient Tablets 20mg
05/23/2016 - 00:28 Astellas, Daiichi Sankyo, and Takeda Announce Research Collaboration on Establishing Biomarker Database on Healthy Adults
05/18/2016 - 20:37 Antiepileptic lacosamide filed for partial amendment of approval to add a new indication in Japan
02/17/2016 - 05:23 Daiichi Sankyo Launches Once-Daily LIXIANA Sales Alliance in Europe
02/10/2016 - 18:26 Daiichi Sankyo Joint Development Product Designated Under SAKIGAKE Designation System
02/02/2016 - 10:56 Daiichi Sankyo to Expand Access to Clinical Trial Data
01/28/2016 - 11:38 Daiichi Sankyo Selected for RobecoSAM Industry Mover Sustainability Award 2016
01/12/2016 - 01:06 Daiichi Sankyo Announces Results of Phase 3 International Joint Trial (RApsody) of Investigational Etanercept Biosimilar
11/24/2015 - 11:58 "Squarekids® subcutaneous injection syringe", a tetravalent combination vaccine for the prevention of diphtheria, pertussis, tetanus, and poliomyelitis (polio) will be launched
10/30/2015 - 20:57 FDA Grants Breakthrough Therapy Designation for Daiichi Sankyo and Plexxikon’s Investigational CSF-1R Inhibitor Pexidartinib (PLX3397) in Tenosynovial Giant Cell Tumor
Copy and paste this code to display this page on your website .
Syndicate content